Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult3. fázis

Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis

A legfontosabb adatok

Ki végzi
Assistance Publique - Hôpitaux de Paris
Hol
Franciaország és Guadeloupe24 helyszín, 2 országbanVálassz országot a helyszínekhez
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
176 fő, tervezett
Kezdés
2026. ápr.
Várható befejezés
2030. febr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Etoposide (Early strategy)
  • Etoposide (Delayed strategy)
A regiszteradat frissítve
2026. április 23.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults in intensive care with a first episode of severe hemophagocytic lymphohistiocytosis (HLH), an immune overreaction, causing organ failure. It compares giving etoposide early versus later.

Életkor
18 years and older.
Nem
All sexes can join.
A betegség stádiuma
Confirmed first episode of HLH, admitted to intensive care, with failure of at least one organ: circulation, breathing, kidneys (stage 2 or higher by KDIGO) or brain (GCS ≤ 13).
Korábbi kezelés
Cannot join if treated with etoposide before intensive care admission, after CAR-T cell therapy, or if HLH started within 15 days after chemotherapy for cancer or a blood cancer.
Biomarker vagy leletérték
HScore of 169 or more.

A részvétel fő kizáró okai

  • Dying patients with shock needing noradrenaline > 2.5 µg/kg/min
  • Etoposide cannot be given within 12 hours
  • Allergy to etoposide or dexamethasone, or unable to take dexamethasone
  • Pregnant or breastfeeding women, or pregnancy not ruled out
  • Recent live attenuated vaccine, or taking part in another interventional study

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult patient
  • Confirmed diagnosis of HLH:; Hscore ≥ 169; Diagnosis of HLH established by the multidisciplinary team caring for the patient(A 24/7 hotline will be available in case of diagnostic uncertainty: this will be the direct line to the on-call intensivist at Avicenne Hospital, who can contact the coordinating investigator as needed)
  • First episode of HLH
  • Admission to intensive care unit
  • Presence of one or more organ failures:; Circulatory: mBP < 65 mmHg with lactate > 2 mmol/L, or treatment with catecholamines; Respiratory: oxygen therapy > 6 L/min or need for non-invasive ventilation, high-flow nasal cannula oxygen therapy, or invasive mechanical ventilation; Renal: stage 2 or higher according to KDIGO criteria, defined by a creatinine increase ≥ 2 times baseline, or urine output < 0.5 mL/kg/h for ≥ 12 hours, or initiation of renal replacement therapy; Neurological: GCS ≤ 13

Ki nem vehet részt

  • Patient treated with etoposide prior to admission to the intensive care unit
  • Recent vaccination with a live attenuated vaccine
  • Moribund patient with refractory distributive shock: multi-organ failure requiring noradrenaline > 2.5 µg/kg/min and imminent risk of death
  • Hypersensitivity to etoposide or any of its excipients
  • Hypersensitivity or contraindication to dexamethasone or any of its excipients, as described in the package insert for the dexamethasone specialty used in the trial and in the protocol
  • Patient with a history of CAR-T cell therapy
  • Patient developing HLH within 15 days following chemotherapy for cancer or hematologic malignancy
  • Pregnant women (positive βhCG), women for whom pregnancy has not been excluded (βhCG not performed in women of childbearing age), or lactating women
  • Inability to administer etoposide within 12 hours
  • Patient not covered by social security
  • Patient under legal guardianship, tutelage, or curatorship
  • Minor patient
  • Participation in another interventional research study

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-term prognosis is compromised (1-month mortality: 30 to 40%).

A teljes eredeti leírásKevesebb

Therapeutic management is urgent and consists in treating associated pathologies and employing immunomodulatory therapy. Currently, there are no clear and consistent recommendations for guiding immunomodulatory treatment in HLH due to the lack of high-level evidence studies. Experts recommend corticosteroid therapy for mild forms, whereas etoposide is proposed for severe cases, especially those with organ failures. However, in clinical practice, its use in patients with multi-organ failure is not systematic due to concerns about potential severe side effects and uncertainty regarding the contribution of severe sepsis to the clinical and biological presentation. Consequently, initiation of etoposide is sometimes delayed.

Our hypothesis is that early treatment of severe HLH associated with organ failure using etoposide could reduce organ failures associated with this syndrome. Therefore, we aim to compare two strategies for initiating etoposide in severe HLH in intensive care: an early strategy where etoposide is prescribed at the onset of HLH-related organ failure, and a delayed strategy where etoposide is prescribed only if there is unfavorable progression (or lack of improvement) after treating associated pathologies, associated with corticosteroid therapy.

A vizsgálat 2 csoportja

  • Early strategyA vizsgált kezelés

    Etoposide treatment will be administered within 12 hours of inclusion.

    Kezelés: Etoposide (Early strategy)

  • Delayed strategyMár használt kezelés, összehasonlításként

    The need for etoposide treatment will be reassessed after 48 hours of management. If organ failure worsens or fails to improve (modified SOFA increase ≥1 point or stable), etoposide will be administered within 12 hours of reassessment. In cases of rapidly deteriorating clinical status with short-term life-threatening prognosis (defined as an increase of 6 or more points in modified SOFA score), patients may receive rescue treatment (before 48 hours) with etoposide at the discretion of the medical team managing the patient; in such cases, the Day-2 infusion will not be administered.

    Kezelés: Etoposide (Delayed strategy)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis in Intensive Care: a Randomized Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. április 23.